|Videos|November 15, 2022

Dr. Morris on challenge of fixed reimbursement vs rising inflation in urology

Author(s)Urology Times staff

“From just a regular business sense, we can’t raise prices to offset some of our supply cost problems,” says David Morris, MD.

At the LUGPA 2022 Annual Meeting, David Morris, MD, Urology Associates, Nashville, TN, discussed challenges facing urology practices in an interview with Urology Times. In this video, he focuses on the difficulties urology practices have faced amid the ongoing inflation crisis.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related to this article

Adding perioperative pembrolizumab to chemotherapy does not improve EFS in MIBC

October 23rd, 2026

Adding perioperative pembrolizumab to chemotherapy does not improve EFS in MIBC

At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.

ESMO 2026: Key presentations across genitourinary oncology

October 20th, 2026

ESMO 2026: Key presentations across genitourinary oncology

Take a look through some of the notable data presentations at this year's ESMO Congress.

Trending on Urology Times

ESMO 2026: Key presentations across genitourinary oncology

How PSMA-PET shapes staging and recurrence workup in prostate cancer

Darolutamide associated with less cognitive change than enzalutamide in prostate cancer

European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC

Gedatolisib plus darolutamide shows preliminary activity in mCRPC